BTG plc (BTG) Receives GBX 777.57 Consensus Price Target from Analysts

Shares of BTG plc (LON:BTG) have earned a consensus rating of “Buy” from the nine brokerages that are currently covering the firm, reports. Two analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is GBX 780.43 ($10.96).

Several equities research analysts have weighed in on BTG shares. Deutsche Bank reaffirmed a “buy” rating and issued a GBX 775 ($10.88) target price on shares of BTG in a research report on Friday, October 6th. Numis Securities reaffirmed a “buy” rating and issued a GBX 900 ($12.64) target price on shares of BTG in a research report on Friday, December 8th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of BTG in a research report on Wednesday, November 15th. Finally, Peel Hunt reaffirmed a “hold” rating and issued a GBX 680 ($9.55) target price on shares of BTG in a research report on Tuesday, November 14th.

Shares of BTG (LON:BTG) traded down GBX 17 ($0.24) on Tuesday, reaching GBX 717 ($10.07). The company had a trading volume of 480,388 shares, compared to its average volume of 522,453. BTG has a 52-week low of GBX 531 ($7.46) and a 52-week high of GBX 784 ($11.01). The company has a market capitalization of $2,780.00 and a PE ratio of 3,773.68.

BTG (LON:BTG) last announced its quarterly earnings data on Tuesday, November 14th. The company reported GBX 21 ($0.29) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of GBX 21 ($0.29). BTG had a return on equity of 10.80% and a net margin of 15.50%. The firm had revenue of £341.30 million for the quarter.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at

BTG Company Profile

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.

Analyst Recommendations for BTG (LON:BTG)

Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with's FREE daily email newsletter.

Leave a Reply